DNDi America Latina

General

Jobs • 0

Shortlists/Awards • 0

Pricing strategy • 0

Partners/Competitors • 0

Last update: Dec 6, 2024 Last update: Dec 6, 2024

General

Jobs

Shortlists/Awards

Pricing strategy

Partners/Competitors

Details

Legal residence:Brazil

Organization type:NGO

Funding agencies:

KFW, UNDP, WB, AFD, WHO

Reconstruction Credit Institute /Kreditanstalt fur Wiederaufbau (HQ), United Nations Development Programme (HQ), World Bank HQ, French Development Agency (HQ), World Health Organization (HQ)

Sectors:

Health, Humanitarian Aid & Emergency, Laboratory & ...
See more

Health, Humanitarian Aid & Emergency, Laboratory & Measurement, Research, Science & Innovation

Nr. of employees:201-500

Sanctions:Check now

Status:

Active

Attachments • 0

About

Drugs for Neglected Diseases initiative (DNDi) is an independent, not-for-profit drug development initiative established in 2003 by five publicly-funded research organizations – Malaysian Ministry of Health, Kenya Medical Research Institute, Indian Council of Medical Research, Oswaldo Cruz Foundation Brazil, and the Institut Pasteur – as well as an international humanitarian organization, Médecins Sans Frontières.

The UNICEF/UNDP/World Bank/WHO’s Special Programme for Research and Training in Tropical Diseases (TDR) is a permanent observer. With a robust portfolio, DNDi aims to develop new, improved, and field-relevant drugs for neglected diseases, including leishmaniasis, human African trypanosomiasis (sleeping sickness), Chagas disease, malaria, specific helminth infections, and paediatric HIV, which afflict the poorest populations of the world.